The prevalence and incidence of Parkinson’s disease (PD) is increasing due to a prolonged life expectancy. This highlights the need for a better mechanistic understanding and new therapeutic approaches. However, traditional in vitro and in vivo experimental models to study PD are suboptimal, thus hampering the progress in the field. The epigenetic reprogramming of somatic cells to induced pluripotent stem cells (iPSCs) offers a unique way to overcome this problem, as these cells share many properties of embryonic stem cells (ESCs) including the potential to be transformed into different lineages. PD modeling with iPSCs is nowadays facilitated by the growing availability of high-efficiency neural-specific differentiation protocols and the possibility to correct or induce mutations as well as creating marker cell lines using designer nucleases. These technologies, together with steady advances in human genetics, will likely introduce profound changes in the way we interpret PD and develop new treatments. Here, we summarize the different PD iPSCs reported so far and discuss the challenges for disease modeling using these cell lines.
PoeweWAntoniniAZijlmansJCBurkhardPRVingerhoetsF. Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. Clin Interv Aging2010; 5: 229–38.
6.
BarbeauA. Parkinson’s disease: clinical features and etiopathology1986; Vol. 49. Amsterdam: Elsevier Science Publishers, pp. 87–152.
7.
BonifatiV. Genetics of Parkinson’s disease—state of the art, 2013. Parkinsonism Relat Disord2014; 20(Suppl 1): S23–8.
8.
MartinIDawsonVLDawsonTM. Recent advances in the genetics of Parkinson’s disease. Annu Rev Genom Hum Genet2011; 12: 301–25.
RakovicAGrunewaldASeiblerPRamirezAKockNOrolickiSLohmannKKleinC. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Hum Mol Genet2010; 19: 3124–37.
12.
Lee Y, Dawson VL and Dawson T M. Animal models of Parkinson’s disease: vertebrate genetics. vol. 2. Cold Spring Harbor Perspectives in Medicine, 2012..
13.
BoveJPerierC. Neurotoxin-based models of Parkinson’s disease. The Journal of Neuroscience2012; 211: 51–76.
14.
TakahashiKYamanakaS. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell2006; 126: 663–76.
15.
ZhouTBendaCDunzingerSHuangYHoJCYangJWangYZhangYZhuangQLiYBaoXTseHFGrillariJGrillari-VoglauerRPeiDEstebanMA. Generation of human induced pluripotent stem cells from urine samples. Nat Protoc2012; 7: 2080–9.
16.
HusseinSMNagyAA. Progress made in the reprogramming field: new factors, new strategies and a new outlook. Curr Opin Genet Dev2012; 22: 435–43.
17.
HartfieldEMFernandesHJVowlesJCowleySAWade-MartinsR. Cellular reprogramming: a new approach to modelling Parkinson’s disease. Biochem Soc Trans2012; 40: 1152–7.
DevineMJRytenMVodickaPThomsonAJBurdonTHouldenHCavaleriFNaganoMDrummondNJTaanmanJWSchapiraAHGwinnKHardyJLewisPAKunathT. Parkinson’s disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat Commun2011; 2: 440–440.
20.
ByersBCordBNguyenHNSchuleBFennoLLeePCDeisserothKLangstonJWPeraRRPalmerTD. SNCA triplication Parkinson’s patient’s iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress. PloS One2011; 6: e26159–e26159.
21.
ChungCYKhuranaVAuluckPKTardiffDFMazzulliJRSoldnerFBaruVLouYFreyzonYChoSMungenastAEMuffatJMitalipovaMPluthMDJuiNTSchuleBLippardSJTsaiLHKraincDBuchwaldSLJaenischRLindquistS. Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. Science2013; 342: 983–7.
22.
RyanSDDolatabadiNChanSFZhangXAkhtarMWParkerJSoldnerFSunicoCRNagarSTalantovaMLeeBLopezKNutterAShanBMolokanovaEZhangYHanXNakamuraTMasliahEYatesJR IIINakanishiNAndreyevAYOkamotoSJaenischRAmbasudhanRLiptonSA. Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1alpha transcription. Cell2013; 155: 1351–64.
23.
NguyenHNByersBCordBShcheglovitovAByrneJGujarPKeeKSchuleBDolmetschRELangstonWPalmerTDPeraRR. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell2011; 8: 267–80.
24.
Sanchez-DanesARichaud-PatinYCarballo-CarbajalIJimenez-DelgadoSCaigCMoraSDi GuglielmoCEzquerraMPatelBGiraltACanalsJMMemoMAlberchJLopez-BarneoJVilaMCuervoAMTolosaEConsiglioARayaA. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson’s disease. EMBO Mol Med2012; 4: 380–95.
25.
CooperOSeoHAndrabiSGuardia-LaguartaCGraziottoJSundbergMMcLeanJRCarrillo-ReidLXieZOsbornTHargusGDeleidiMLawsonTBogetofteHPerez-TorresEClarkLMoskowitzCMazzulliJChenLVolpicelli-DaleyLRomeroNJiangHUittiRJHuangZOpalaGScarffeLADawsonVLKleinCFengJRossOATrojanowskiJQLeeVMMarderKSurmeierDJWszolekZKPrzedborskiSKraincDDawsonTMIsacsonO. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson’s disease. Sci Transl Med2012; 4: 141ra90–141ra90.
26.
LiuGHQuJSuzukiKNivetELiMMontserratNYiFXuXRuizSZhangWWagnerUKimARenBLiYGoeblAKimJSoligallaRDDubovaIThompsonJYatesJ IIIEstebanCRSancho-MartinezIIzpisua BelmonteJC. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature2012; 491: 603–7.
27.
ReinhardtPSchmidBBurbullaLFSchondorfDCWagnerLGlatzaMHoingSHargusGHeckSADhingraAWuGMullerSBrockmannKKlubaTMaiselMKrugerRBergDTsytsyuraYThielCSPsathakiOEKlingaufJKuhlmannTKlewinMMullerHGasserTScholerHRSterneckertJ. Genetic correction of a LRRK2 mutation in human iPSCs links Parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell2013; 12: 354–67.
28.
OrensteinSJKuoSHTassetIAriasEKogaHFernandez-CarasaICortesEHonigLSDauerWConsiglioARayaASulzerDCuervoAM. Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci2013; 16: 394–406.
29.
SuYCQiX. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Hum Mol Genet2013; 22: 4545–61.
30.
SandersLHLaganiereJCooperOMakSKVuBJHuangYAPaschonDEVangipuramMSundararajanRUrnovFDLangstonJWGregoryPDZhangHSGreenamyreJTIsacsonOSchuleB. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson’s disease patients: reversal by gene correction. Neurobiol Dis2014; 62: 381–6.
31.
SeiblerPGraziottoJJeongHSimunovicFKleinCKraincD. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J Neurosci2011; 31: 5970–6.
32.
RakovicAShurkewitschKSeiblerPGrunewaldAZanonAHagenahJKraincDKleinC. PTEN-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous Parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem (iPS) cell-derived neurons. J Biol Chem2012; 4: 380–95.
33.
MillerJDGanatYMKishinevskySBowmanRLLiuBTuEYMandalPKVeraEShimJWKriksSTaldoneTFusakiNTomishimaMJKraincDMilnerTARossiDJStuderL. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell2013; 13: 691–705.
34.
JiangHRenYYuenEYZhongPGhaediMHuZAzabdaftariGNakasoKYanZFengJ. Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nat Commun2012; 3: 668–668.
35.
ImaizumiYOkadaYAkamatsuWKoikeMKuzumakiNHayakawaHNihiraTKobayashiTOhyamaMSatoSTakanashiMFunayamaMHirayamaASogaTHishikiTSuematsuMYagiTItoDKosakaiAHayashiKShoujiMNakanishiASuzukiNMizunoYMizushimaNAmagaiMUchiyamaYMochizukiHHattoriNOkanoH. Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain2012; 5: 35–35.
36.
AboudAATidballAMKumarKKNeelyMDEssKCEriksonKMBowmanAB. Genetic risk for Parkinson’s disease correlates with alterations in neuronal manganese sensitivity between two human subjects. Neurotoxicology2012; 33: 1443–9.
ElkabetzYPanagiotakosGAl ShamyGSocciNDTabarVStuderL. Human ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. Genes Dev2008; 22: 152–65.
39.
KimBKKimSEShimJHWooDHGilJEKimSKKimJH. Neurogenic effect of vascular endothelial growth factor during germ layer formation of human embryonic stem cells. FEBS Lett2006; 580: 5869–74.
40.
PerrierALTabarVBarberiTRubioMEBrusesJTopfNHarrisonNLStuderL. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA2004; 101: 12543–8.
41.
RoyNSClerenCSinghSKYangLBealMFGoldmanSA. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med2006; 12: 1259–68.
42.
SonntagKCPruszakJYoshizakiTvan ArensbergenJSanchez-PernauteRIsacsonO. Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin. Stem Cell2007; 25: 411–8.
43.
Sanchez-DanesAConsiglioARichaudYRodriguez-PizaIDehayBEdelMBoveJMemoMVilaMRayaABelmonteJCI. Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells. Hum Gene Ther2012; 23: 56–69.
44.
YanYYangDZarnowskaEDDuZWerbelBValliereCPearceRAThomsonJAZhangSC. Directed differentiation of dopaminergic neuronal subtypes from human embryonic stem cells. Stem Cell2005; 23: 781–90.
45.
OkadaYMatsumotoAShimazakiTEnokiRKoizumiAIshiiSItoyamaYSobueGOkanoH. Spatiotemporal recapitulation of central nervous system development by murine embryonic stem cell-derived neural stem/progenitor cells. Stem Cell2008; 26: 3086–98.
46.
NeelyMDLittMJTidballAMLiGGAboudAAHopkinsCRChamberlinRHongCCEssKCBowmanAB. DMH1, a highly selective small molecule BMP inhibitor promotes neurogenesis of hiPSCs: comparison of PAX6 and SOX1 expression during neural induction. ACS Chem Neurosci2012; 3: 482–91.
47.
KriksSShimJWPiaoJGanatYMWakemanDRXieZCarrillo-ReidLAuyeungGAntonacciCBuchAYangLBealMFSurmeierDJKordowerJHTabarVStuderL. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature2011; 480: 547–51.
48.
ChambersSMFasanoCAPapapetrouEPTomishimaMSadelainMStuderL. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol2009; 27: 275–80.
49.
CooperOHargusGDeleidiMBlakAOsbornTMarlowELeeKLevyAPerez-TorresEYowAIsacsonO. Differentiation of human ES and Parkinson’s disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol Cell Neurosci2010; 45: 258–66.
50.
Frank-KamenetskyMZhangXMBottegaSGuicheritOWichterleHDudekHBumcrotDWangFYJonesSShulokJRubinLLPorterJA. Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists. J Biol2002; 1: 10–10.
51.
ChenJKTaipaleJYoungKEMaitiTBeachyPA. Small molecule modulation of smoothened activity. Proc Natl Acad Sci USA2002; 99: 14071–6.
52.
LiWSunWZhangYWeiWAmbasudhanRXiaPTalantovaMLinTKimJWangXKimWRLiptonSAZhangKDingS. Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors. Proc Natl Acad Sci USA2011; 108: 8299–304.
53.
KimJEO’SullivanMLSanchezCAHwangMIsraelMABrennandKDeerinckTJGoldsteinLSGageFHEllismanMHGhoshA. Investigating synapse formation and function using human pluripotent stem cell-derived neurons. Proc Natl Acad Sci USA2011; 108: 3005–10.
54.
Mak SK, Huang YA, Iranmanesh S, Vangipuram M, Sundararajan R, Nguyen L, Langston JW and Schule B. Small molecules greatly improve conversion of human-induced pluripotent stem cells to the neuronal lineage. Stem Cell Int 2012; 31(16):5970--6.
55.
BuganimYFaddahDAJaenischR. Mechanisms and models of somatic cell reprogramming. Nat Rev Genet2013; 14: 427–39.
56.
LiangGZhangY. Genetic and epigenetic variations in iPSCs: potential causes and implications for application. Cell Stem Cell2013; 13: 149–59.
57.
HuQFriedrichAMJohnsonLVCleggDO. Memory in induced pluripotent stem cells: reprogrammed human retinal-pigmented epithelial cells show tendency for spontaneous redifferentiation. Stem Cell2010; 28: 1981–91.
58.
PoloJMLiuSFigueroaMEKulalertWEminliSTanKYApostolouEStadtfeldMLiYShiodaTNatesanSWagersAJMelnickAEvansTHochedlingerK. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol2010; 28: 848–55.
59.
LaurentLCUlitskyISlavinITranHSchorkAMoreyRLynchCHarnessJVLeeSBarreroMJKuSMartynovaMSemechkinRGalatVGottesfeldJIzpisua BelmonteJCMurryCKeirsteadHSParkHSSchmidtULaslettALMullerFJNievergeltCMShamirRLoringJF. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell2011; 8: 106–18.
60.
BockCKiskinisEVerstappenGGuHBoultingGSmithZDZillerMCroftGFAmorosoMWOakleyDHGnirkeAEgganKMeissnerA. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell2011; 144: 439–52.
61.
BoultingGLKiskinisECroftGFAmorosoMWOakleyDHWaingerBJWilliamsDJKahlerDJYamakiMDavidowLRodolfaCTDimosJTMikkilineniSMacDermottABWoolfCJHendersonCEWichterleHEgganK. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol2011; 29: 279–86.
62.
HuBYWeickJPYuJMaLXZhangXQThomsonJAZhangSC. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci USA2010; 107: 4335–40.
63.
GajTGersbachCABarbasCF III. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol2013; 31: 397–405.
64.
SoldnerFLaganiereJChengAWHockemeyerDGaoQAlagappanRKhuranaVGolbeLIMyersRHLindquistSZhangLGuschinDFongLKVuBJMengXUrnovFDRebarEJGregoryPDZhangHSJaenischR. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell2011; 146: 318–31.
65.
GuptaAMengXZhuLJLawsonNDWolfeSA. Zinc finger protein-dependent and -independent contributions to the in vivo off-target activity of zinc finger nucleases. Nucleic Acids Res2011; 39: 381–92.
66.
FuYFodenJAKhayterCMaederMLReyonDJoungJKSanderJD. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol2013; 31: 822–6.
67.
MekhoubadSBockCde BoerASKiskinisEMeissnerAEgganK. Erosion of dosage compensation impacts human iPSC disease modeling. Cell Stem Cell2012; 10: 595–609.
68.
BrinkmanABRoelofsenTPenningsSWMartensJHJenuweinTStunnenbergHG. Histone modification patterns associated with the human X chromosome. EMBO Rep2006; 7: 628–34.
69.
YuJHuKSmuga-OttoKTianSStewartRSlukvinIIThomsonJA. Human induced pluripotent stem cells free of vector and transgene sequences. Science2009; 324: 797–801.
70.
SandoeJEgganK. Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. Nat Neurosci2013; 16: 780–9.
71.
CroisierEGraeberMB. Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathol2006; 112: 517–30.
72.
LobsigerCSClevelandDW. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci2007; 10: 1355–60.
73.
RansomBRKunisDMIrwinILangstonJW. Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neurosci Lett1987; 75: 323–8.
74.
ZhouWLeeYMGuyVCFreedCR. Embryonic stem cells with GFP knocked into the dopamine transporter yield purified dopamine neurons in vitro and from knock-in mice. Stem Cell2009; 27: 2952–61.
75.
PangZPYangNVierbuchenTOstermeierAFuentesDRYangTQCitriASebastianoVMarroSSudhofTCWernigM. Induction of human neuronal cells by defined transcription factors. Nature2011; 476: 220–3.
76.
ZhangYPakCHanYAhleniusHZhangZChandaSMarroSPatzkeCAcunaCCovyJXuWYangNDankoTChenLWernigMSudhofTC. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron2013; 78: 785–98.
77.
ChintaSJLieuCADemariaMLabergeRMCampisiJAndersenJK. Environmental stress, ageing and glial cell senescence: a novel mechanistic link to Parkinson’s disease?J Intern Med2013; 273: 429–36.
78.
LancasterMARennerMMartinCAWenzelDBicknellLSHurlesMEHomfrayTPenningerJMJacksonAPKnoblichJA. Cerebral organoids model human brain development and microcephaly. Nature2013; 501: 373–9.
